You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 10,052,389


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,052,389
Title:Polymeric system for release of an active agent
Abstract: The present disclosure relates to a polymeric system for release of an active agent, comprising a first polymeric phase containing the active agent, the first polymeric phase forming discrete regions of a set size range and being dispersed within a second polymeric phase comprising a cross-linked polymer-phenol conjugate for release of the active agent therein. The present disclosure further provides an injectable hydrogel comprising the disclosed polymeric system, a carrier for delivering a biologically active substance or a drug comprising the injectable hydrogel, and a method for producing the disclosed polymeric system.
Inventor(s): Kurisawa; Motoichi (Singapore, SG), Bae; Ki Hyun (Singapore, SG), Lee; Fan (Singapore, SG)
Assignee: Agency for Science, Technology and Research (Singapore, SG)
Application Number:14/767,784
Patent Claims:1. A polymeric system for release of an active agent, having a first polymeric phase comprising polyethylene glycol (PEG) and containing the active agent as a PEG conjugated-active agent, said first polymeric phase forming discrete regions of a set size range and being dispersed within a second polymeric phase comprising a cross-linked dextran-tyramine conjugate for release of the active agent therein, wherein said PEG conjugated-active agent preferentially partitions to said first polymeric phase as compared to said second polymeric phase and wherein the first polymeric phase comprising PEG is not conjugated to the active agent.

2. The polymeric system of claim 1, wherein the second polymeric phase has been formed by utilizing an agent that controls the rate of cross-linking during formation of said second polymeric phase to thereby control the set size range of the discrete regions of the first polymer phase.

3. The polymeric system of claim 2, wherein the agent that controls the rate of cross-linking during polymerization is a catalyst, and wherein said catalyst is selected from the group consisting of horseradish peroxidase, human myeloperoxidase, lactoperoxidase, eosinophil peroxidase, thyroid peroxidase, prostaglandin H synthases, soybean peroxidase, hemin, hematin, microperoxidase-11, and cytochrome c.

4. The polymeric system of claim 1, wherein the rate of release of said active agent from said polymeric system is dependent on the size of said discrete regions, such that smaller discrete regions result in a slower release rate of said active agent from said polymeric system as compared to larger discrete regions.

5. The polymeric system of claim 1, wherein the size of said discrete regions is in the micron-range or the nano-range and the discrete regions form microdomains, microspheres or microcapsules.

6. The polymeric system of claim 1, wherein said active agent is selected from the group consisting of proteins, antibodies, peptides, small-molecule drugs, nucleic acid-based drugs, nanoparticulate systems and mixtures thereof.

7. The polymeric system of claim 1, wherein said PEG conjugated-active agent is PEGinterferon alpha-2a, PEGylated L-asparaginase, PEG-adenosine deaminase, PEGinesatide, PEGylated uricase, PEGylated hyaluronidase, PEGylated epidermal growth factor, PEGylated tumor necrosis factor, PEGylated tumor necrosis factor-related apoptosis-inducing ligand, certolizumab pegol, PEGylated erythropoetin, PEGaptanib, PEGylated recombinant methionyl human granulocyte colony-stimulating factor, PEG-human growth hormone mutein antagonists and PEGylated interferon alpha-2b.

8. An injectable hydrogel for release of an active agent, having a first polymeric phase comprising polyethylene glycol (PEG) and containing the active agent as a PEG conjugated-active agent, said first polymeric phase forming discrete regions of a set size range and being dispersed within a second polymeric phase comprising a cross-linked dextran-tyramine conjugate for release of the active agent therein, wherein said PEG conjugated-active agent preferentially partitions to said first polymeric phase as compared to said second polymeric phase and wherein the first polymeric phase comprising PEG is not conjugated to the active agent.

9. A method for forming a polymeric system for release of an active agent, having a first polymeric phase comprising polyethylene glycol (PEG) and containing the active agent as a PEG conjugated-active agent, said first polymeric phase forming discrete regions of a set size range and being dispersed within a second polymeric phase comprising a cross-linked dextran-tyramine conjugate for release of the active agent therein, wherein said PEG conjugated-active agent preferentially partitions to said first polymeric phase as compared to said second polymeric phase and wherein the first polymeric phase comprising PEG is not conjugated to the active agent, the method comprising the steps of: a) providing an aqueous reaction mixture comprising the first polymeric phase polymer, the dextran-tyramine conjugate and the PEG conjugated-active agent; and b) controlling the rate of cross-linking of said dextran-tyramine conjugate during formation of said second polymeric phase to thereby control the set size range of the discrete regions of the first polymeric phase having the PEG conjugated-active agent therein.

10. The method of claim 9, comprising the step of adding an agent that controls the rate of cross-linking of said second polymeric phase to said reaction mixture.

11. The method of claim 10, comprising the step of selecting the concentration of said agent to thereby control the rate of cross-linking of said second polymeric phase.

12. The method of claim 9, wherein said cross-linking step involves the formation of a C--C bond or C--O bond between a pair of dextran-tyramine conjugates.

13. The method of claim 9, comprising the step of adding an oxidizing agent to said reaction mixture, wherein said oxidizing agent is a peroxide selected from hydrogen peroxide, sodium peroxide, potassium peroxide, hydrogen superoxide, potassium superoxide, alkyl peroxides, aryl peroxides, acyl peroxides, organic hydroperoxides, organic peracids, sodium percarbonate, ammonium persulfate and perborates.

14. The method of claim 9, wherein said crosslinking is carried out for 1 to 60 minutes, or at a temperature of 4.degree. C. to 40.degree. C.

15. The method of claim 10, wherein said agent is a catalyst, wherein said catalyst is an enzyme selected from horseradish peroxidase, human myeloperoxidase, lactoperoxidase, eosinophil peroxidase, thyroid peroxidase, prostaglandin H synthases, soybean peroxidase, hemin, hematin, microperoxidase-11, and cytochrome c.

16. The polymeric system of claim 1, wherein said active agent is selected from the group consisting of insulin, bovine serum albumin and interferon.

Details for Patent 10,052,389

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 05/05/2004 ⤷  Try a Trial 2033-02-13
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 12/02/2004 ⤷  Try a Trial 2033-02-13
Amphastar Pharmaceuticals, Inc. AMPHADASE hyaluronidase Injection 021665 10/26/2004 ⤷  Try a Trial 2033-02-13
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.